



## Thursday, November 7, 2019

7:30 *Registration*

08:30 - 09:30 UVEITIS  
Chair: **Ron Neumann**, Israel

### LONG TERM SYSTEMIC EFFECTS OF IMMUNOSUPPRESSIVE DRUGS

8:30 Steroids  
**Francine Behar-Cohen**, France

8:35 TNF inhibitors  
**Alfredo Adan**, Spain

8:40 Methotrexate  
**William Ayliffe**, UK

8:45 Mycophenolate mofetil  
**Marc de Smet**, Switzerland

8:50 Discussion  
**Session Speakers**  
Moderator: **Ron Neumann**, Israel

Total burden on health of systemic therapy  
Topical/systemic drugs decision making  
Allowing development of cataract vs. long term effects of systemic therapy  
The art of discontinuing systemic therapy  
Vaccinations and epidemics in modern times and the immunosuppressed patient

9:30 *Coffee Break*

10:00 - 11:00 KEYNOTE LECTURE & FREE PAPERS  
Chair: **Baruch Kuppermann**, USA

### KEYNOTE LECTURE:

10:00 Lessons learned in ophthalmic biotech as a CEO, venture capitalist and clinician  
**David Guyer**, USA

### FREE PAPERS

10:15 The 3-year RETRO-IDEAL study – comparing visual acuity outcomes in patients with poor and good baseline vision  
**Albert J. Augustin**, Germany

10:20 Real-world evidence in DME with aflibercept: 24 months of follow-up  
**Patricia Udaondo**, Spain



## Thursday, November 7, 2019 (Continued)

10:00 - 11:00 **KEYNOTE LECTURE & FREE PAPERS (Continued)**  
Chair: **Baruch Kuppermann**, USA

- 10:25 Correlation of OCT biomarkers with aqueous humor biopsy results in DME  
**Paula Martínez López Corell**, Spain
- 10:30 Diabetic macular edema (DME) treatment, responders and nonresponders  
**Enesa Begovic**, Bosnia and Herzegovina
- 10:35 Importance of inflammation in choroidal thinning in diabetes  
**Martin Puzo Bayod**, Spain
- 10:40 Transplantation of human iPS cells-derived RPE cell suspension into the subretinal space of a swine model of geographic atrophy  
**Lucia Lee Ferraro**, Spain
- 10:45 Biodegradable intraocular implant loaded with adenosine A3 receptor agonist affords protection against retinal ischemic injury  
**Ana Raquel Santiago**, Portugal
- 10:50 Pharmacokinetics and tissue distribution of atropine after single and repeated topical instillation in rabbits  
**Xin Zhao**, China
- 10:55 Q&A

11:00 - 12:00 **ENDOPHTHALMITIS**  
Chair: **Anat Loewenstein**, Israel

- 11:00 Intraocular drug-related complications of endophthalmitis prophylaxis  
**Tat Keong Chan**, Singapore
- 11:10 Diagnostic vitrectomy for suspect endophthalmitis  
**Anat Loewenstein**, Israel
- Panel: antibiotics for intraocular infections?  
Moderator: **Anat Loewenstein**, Israel
- Discussants:  
**Patricia Udaondo**, Spain  
**Alfredo Adan**, Spain  
**Alfredo Garcia-Layana**, Spain
- How should antibiotics be used? For how long?  
Vitrectomy - when?



## Thursday, November 7, 2019 (Continued)

11:00 - 12:00 **ENDOPHTHALMITIS (Continued)**  
Chair: **Anat Loewenstein**, Israel

- 11:40 CMV retinitis in iatrogenic immunosuppression: role for intravitreal ganciclovir  
**Ana Maria Cunha**, Portugal
- 11:45 Human herpesvirus type 6 - the unlikely agent  
**Ana Maria Cunha**, Portugal
- 11:50 Ozurdex implant migration into the anterior chamber: risk factors and management  
**Siddarth Nardeosingh**, UK
- 11:55 Bilateral simultaneous neovascularization associated to chorioretinal lesions in a patient with previous non-filiated chronic anterior uveitis: which is the diagnosis?  
**Raquel Burggraaf Sánchez De Las Matas**, Spain

---

12:00 *Lunch*

---

12:30 - 13:30 **FREE PAPERS**  
Chair: **Baruch Kuppermann**, USA

- 12:30 Primary results from phase 2 Study of risuteganib in intermediate dry age-related macular degeneration  
**Baruch Kuppermann**, USA
- 12:40 One year outcomes of 4-week extension of treatment interval in a treat-and-extend regimen with aflibercept for exudative age-related macular degeneration  
**Teresa Diago**, Spain
- 12:45 Ranibizumab vs aflibercept for neovascular AMD in an innovative setting for intravitreal injection: bari policlinico real-world experience  
**Maria Oliva Grassi**, Italy
- 12:50 Time to dry analysis of brolocizumab versus aflibercept in patients with neovascular age-related macular degeneration: 96-week data from the HAWK and HARRIER trials  
**Javier Montero Hernandez**, Spain
- 12:55 Simultaneous neutralization of angiopoietin-2 (Ang-2) and vascular endothelial growth factor-A (VEGF-A) with faricimab: a review of the phase 2 clinical trials in neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME)  
**Jordi Mones**, Spain
- 13:00 Management of chronic central serous chorioretinopathy with mineralcorticoide and nanosecond laser  
**Marina Aguilar González**, Spain



## Thursday, November 7, 2019 (Continued)

12:30 - 13:30 **FREE PAPERS (Continued)**  
Chair: **Baruch Kuppermann**, USA

- 13:05 Improving diagnosis in chronic serous corioretinopathy  
**Miriam Rahhal Ortuño**, Spain
- 13:10 Trimethoprim / Sulfamethoxazole as a first-line treatment in ocular toxoplasmosis  
**Alex Samir Fernández Santodomingo**, Spain
- 13:15 Intravitreal dexamethasone implant use in coats disease  
**Rodrigo Molina Pallete**, Spain
- 13:20 Q&A

13:30 - 15:30 **MANAGEMENT OF AMD**

13:30 - 14:50 **PART 1: IMAGING AND MANAGEMENT IN AMD**  
Chairs: **Karina Berg**, Norway & **Paolo Lanzetta**, Italy

### A. IMAGING: DIAGNOSIS AND FOLLOW UP

- 13:30 OCT angiography biomarkers in neovascular AMD  
**Luis Arias Barquet**, Spain
- 13:35 Imaging in dry AMD  
**Alfredo Garcia-Layana**, Spain
- 13:40 Non-exudative CNV; to treat or not?  
**Paolo Lanzetta**, Italy
- 13:45 Hyper-reflective foci in AMD  
**Francesco Bandello**, Italy
- 13:50 Discussion  
Moderator: **Karina Berg**, Norway
- When should we diagnose and treat? prior to clinical finding?  
Current practice and role of imaging in AMD  
Indications for fluorescein/indocyanin green

### B. TREATMENT

- 14:10 Management of polypoidal lesions (Atlantic study)  
**Rufino Silva**, Portugal
- 14:15 Key points of RIVAL study  
**Karina Berg**, Norway



## Thursday, November 7, 2019 (Continued)

13:30 - 15:30 MANAGEMENT OF AMD (Continued)

13:30 - 14:50 PART 1: IMAGING AND MANAGEMENT IN AMD (Continued)  
Chairs: **Karina Berg**, Norway & **Paolo Lanzetta**, Italy

14:20 Treat and extend latest evidence with aflibercept (ALTAIR study)  
**Stela Vujosevic**, Italy

14:25 Retreatment criteria for AMD (FLUID study)  
**Patricia Udaondo**, Spain

14:30 **Discussion**  
Moderator: **Paolo Lanzetta**, Italy

### Does the regimen matter?

Management of bilateral wet AMD  
Evidence or lack of it for ideal regimen  
Evidence for TAE, addressing deteriorating lesions  
Repeat loading dose vs. revert to previous step?  
Guidance to discontinue treatment; the role of visual acuity

14:50 - 15:30 PART 2: THE ROLE OF NEW MOLECULES?  
Chair: **Baruch Kuppermann**, USA

14:50 Brolucizumab  
**Javier Montero Hernandez**, Spain

14:55 Abicipar phase III  
**Baruch Kuppermann**, USA

15:00 Brimonidine tartrate in AMD  
**Albert Augustin**, Germany

15:05 Update on Complement inhibition results  
**Baruch Kuppermann**, USA

15:10 **Discussion**  
Moderator: **Albert Augustin**, Germany

The next strategic step: Improved delivery?  
New Chemical/biological entities vs. available drugs imported from other medical fields  
New non-drug strategies?  
When current therapy becomes ineffective, is there a next step?  
Learning from lampalizumab failure; can we learn from the dementia studies failure?

15:30 *Coffee Break*



## Thursday, November 7, 2019 (Continued)

16:00 - 18:00 **DIABETIC MACULAR EDEMA**  
Chairs: **Patricia Udaondo**, Spain & **Stela Vujosevic**, Italy

### IMAGING IN DME

- 16:00 Prognostic and predictive biomarkers in DME  
**Patricia Udaondo**, Spain
- 16:05 Microvascular changes as predictor for DME progression  
**Maria Cristina Parravano**, Italy
- 16:10 How can we define chronic DME?  
**Stela Vujosevic**, Italy
- 16:15 Discussion  
Moderator: **Stela Vujosevic**, Italy

### DME MANAGEMENT

- 16:30 Real world evidence with fluocinolone implant in DME  
**Francesco Bandello**, Italy
- 16:35 Long term efficacy and safety of dexamethasone implant for DME  
**Alfredo Adan**, Spain
- 16:40 Real life outcomes of anti-VEGF therapy in DME  
**Paolo Lanzetta**, Italy
- 16:45 Take home messages of latest protocols of DRCR.net (T and V)  
**Patricia Udaondo**, Spain
- 16:50 The EURETINA guidelines for DME  
**Karina Berg**, Norway
- 16:55 Combined therapy in DME  
**Enrique Cervera**, Spain
- 17:00 Discussion  
Moderator: **Patricia Udaondo**, Spain
- Combine therapy  
Loading dose  
Treating eyes with good visual acuity  
Interpretation of protocol T results  
Role for surgery



## Thursday, November 7, 2019 (Continued)

16:00 - 18:00 **DIABETIC MACULAR EDEMA (Continued)**  
Chairs: **Patricia Udaondo**, Spain & **Stela Vujosevic**, Italy

### **FORSEEN FUTURE IN DME**

- 17:20 Phase II trials that succeeded and fail for DME: angiopoietin vs Tie2  
**Baruch Kuppermann**, USA
- 17:25 Phase I first-in-human study of KSI-301: a novel anti-VEGF antibody biopolymer conjugate (ABC) with extended durability  
**J. Pablo Velazquez-Martin**, USA
- 17:30 Drugs in pipeline for DME  
**Marc de Smet**, Switzerland
- 17:35 Discussion  
Moderator: **Marc de Smet**, Switzerland

---

18:00 *End of Day's Sessions*

---

## Friday, November 8, 2019

08:30 - 09:30 **ADVANCED AMD**  
Chair: **Usha Chakravarthy**, UK

- 8:30 Review the pathogenesis of AMD and the pathways to CNV and GA  
**Jordi Mones**, Spain
- 8:37 Discussion
- 8:45 Examine current therapeutics and consider the long-term outcomes and unmet need  
**Tunde Peto**, UK
- 8:52 Discussion
- 9:00 Evaluate the current therapeutic pipeline critically assessing the appropriateness of targets  
**Usha Chakravarthy**, UK
- 9:07 Discussion
- 9:15 Home OCT: improving AMD therapy with accessible data  
**Anat Lowenstein**, USA
- 9:22 Discussion

---

9:30 *Coffee Break*

---



## Friday, November 8, 2019 (Continued)

10:00 - 11:00 **ARTIFICIAL INTELLIGENCE**  
Chairs: **Tunde Peto**, UK & **Leopold Schmetterer**, Singapore

- 10:00 Artificial Intelligence in retinal imaging  
**Javier Zarranz**, Spain
- 10:10 Future in imaging. Functional Imaging  
**Tunde Peto**, UK
- 10:20 Artificial Intelligence for glaucoma  
**Leopold Schmetterer**, Singapore
- 10:30 AI in retinal disease - screening and ophthalmologist virtual assistant  
**Tamar Levi Vineberg**, Israel
- 10:40 Discussion

11:00 - 12:00 **GENE THERAPY**  
Chair: **Francine Behar Cohen**, France

- 11:00 Human pluripotent stem cell therapy for the treatment of Retinitis pigmentos  
**Karim Ben Mbarek**, France
- 11:15 Viral gene therapy for wet AMD: where are we?  
**Marc de Smet**, Switzerland
- 11:30 Non viral gene therapy: from concept to human trial  
**Francine Behar-Cohen**, France
- 11:45 Non-viral gene therapy for neuroprotection  
**Karine Bigot**, France

12:00 - 13:30 **COMPANY SPONSORED LUNCH SESSION**

- 12:00 Lunch served
- 12:30 [Sponsored Session - click here to view the program](#)





## Friday, November 8, 2019 (Continued)

13:30 - 15:30 **DRUG DELIVERY**  
Chairs: **Diane Tang Liu**, USA & **Uday Kompella**, USA

- 13:30 Diabetic macular edema: pathophysiology and novel therapeutic agents  
**Arup Das**, USA
- 13:40 Targeted treatment of retinoblastoma with an oncolytic adenovirus  
**Angel Montero Carcaboso**, Spain
- 13:50 Nanoformulation as intraocular drug delivery system to target the posterior segment  
**Martina Giannaccini**, Italy
- 14:00 Microspheres as therapeutic systems to treat retinal diseases  
**Martia Del Rocio Herrero-Varnell**, Spain
- 14:10 Biodegradable intraocular implants  
**Uday Kompella**, USA
- 14:20 Sustained Release of small molecules and biologics using photocrosslinked ocular drug delivery systems  
**Raghu Raj Thakur**, UK
- 14:30 The vitreoretinal explant: a drug delivery model to promote the rational design of nanoparticles for retinal delivery  
**Karen Peynshaert**, Belgium
- 14:40 Suprachoroidal drug delivery  
**Uday Kompella**, USA
- 14:55 Discussion

---

15:30 *Coffee Break*

---



## Friday, November 8, 2019 (Continued)

16:00 - 17:00 **CENTRAL SEROUS CHOROIDOPATHY**  
Chairs: **Francine Behar-Cohen**, France & **Jose María Ruiz Moreno**, Spain

- 16:00 Imaging CSCR by SS-OCT and SS OCT-A  
**Jose María Ruiz Moreno**, Spain
- 16:10 CSCR and blood flow  
**Mathilde Gallice**, France
- 16:20 Current management of CSCR  
**Ibraheem El Ghrably**, Abu Dhabi
- 16:30 CSCR and CNV  
**Jorge Ruiz Medrano**, Spain
- 16:40 Anti-VEGF in neovascular CSCR  
**Francine Behar-Cohen**, France
- 16:50 Change in choroid after half-fluency PDT  
**Ignacio Flores-Moreno**, Spain

17:00 - 17:45 **RETINAL VEIN OCCLUSION**  
Chairs: **Albert Augustin**, Germany & **Manuel Saenz de Viteri**, Spain

- 17:00 Multimodal imaging: assessing non perfusion  
**Albert Augustin**, Germany
- 17:05 The LEAVO trial  
**Usha Chakravarthy**, UK
- 17:10 Long term efficacy of steroids in management of macular edema in vein Occlusion  
**Ibraheem El Ghrably**, Abu Dhabi
- 17:15 Latest evidence of anti VEGF in vein occlusion  
**Choi-Mun Chan**, Singapore
- 17:20 Laser in vein occlusion: when and for what?  
**Manuel Saenz de Viteri**, Spain
- 17:25 Discussion with clinical cases  
Moderator: **Manuel Saenz de Viteri**, Spain

---

17:45 *End of Day's Sessions*

---

15<sup>th</sup> **ISOPT** *Clinical*

The International Symposium on  
Ocular Pharmacology and Therapeutics



Valencia, Spain  
November 7-9, 2019

## Saturday, November 9, 2019

08:00 - 08:45 **INHIBITION OF DIABETIC RETINOPATHY**  
Chair: **Arup Das**, USA

- 8:00 Targeting G-proteins to inhibit Diabetic Retinopathy  
**Renu Kowluru**, USA
- 8:10 Kallikrein-kinin system in diabetic retinopathy - novel target  
**Edward Feener**, USA
- 8:20 Targeting IL-6 signaling to intervene in the progression of diabetic retinopathy  
**Susanne Mohr**, USA
- 8:30 Combotherapy of diabetic retinopathy: emerging paradigm  
**Ashwath Jayagopal**, Switzerland

08:45 - 09:30 **THERAPY OF RETINAL ANGIOGENESIS**  
Chair: **Arup Das**, USA

- 8:45 Non-coding RNA based therapeutics  
**Subrata Chakarabarti**, Canada
- 8:55 Control of retinal angiogenesis by modification of cell membrane lipid composition and membrane fluidity  
**Julia Busik**, USA
- 9:05 Inflammation in early diabetic retinopathy  
**John Penn**, USA
- 9:15 Glial influence in the pathogenesis of diabetic retinopathy  
**Debasish Sinha**, USA

---

9:30 *Coffee Break*

---



## Saturday, November 9, 2019 (Continued)

10:00 - 11:20 **GENE THERAPY**  
Chair: **Neena Haider, USA & Margaret DeAngelis, USA**

- 10:00 Modifier gene therapy as a novel broad spectrum way to treat retinal disease  
**Neena Haider, USA**
- 10:10 Using genomics to characterize therapeutic targets for AMD  
**Margaret DeAngelis, USA**
- 10:20 Precision medicine gene therapy for LCA16  
**Bikash Pattniak, USA**
- 10:30 Gene therapy for X-linked retinitis pigmentosa with codon-optimized AAV8-RPGR  
**Cristina Martinez, UK**
- 10:40 Gene therapy for wet AMD using non-viral vectors  
**Manuel Saenz de Viteri, Spain**
- 10:50 Novel gene therapy approaches for inherited retinal diseases  
**Jordi Mones, Spain**
- 11:00 Q&A

11:20 - 12:00 **KEYNOTE LECTURE & FREE PAPERS**  
Chair: **Ron Neumann, Israel**

### KEYNOTE LECTURE:

- 11:20 Down to earth: harnessing artificial intelligence to improve retinal diagnosis and health  
**Dimitri Azar, USA**

### FREE PAPERS

- 11:35 Uveitis induced by brentuximab vedotin – a novel adverse response to antibody drug conjugate therapy  
**Gal Antman, Israel**
- 11:40 Screening protocol and therapeutic options for the macular edema secondary to fingolimod treatment in patients with multiple sclerosis  
**David Salom, Spain**
- 11:45 A prospective, non-randomized, multicenter study on the efficacy and safety of ILUVIEN® in diabetic macular edema patients considered insufficiently responsive to available therapies (REACT)  
**José María Ruiz Moreno, Spain**
- 11:50 Zimura C5 complement inhibitor Phase 2b results  
**Kourous Rezaei, USA**

12:00 *Lunch*



## Saturday, November 9, 2019 (Continued)

12:30 - 13:30 THE EPHRAIM FRIEDMAN LECTURE & FREE PAPERS  
Chairs: **Usha Chakravarthy**, UK & **Javier Zarranz**, Spain

### THE EPHRAIM FRIEDMAN LECTURE

12:30 Introduction: **Sara Krupsky**, Israel & **Ron Neumann**, Israel

12:40 Neuroprotection for retinal diseases  
**Baruch Kuppermann**, USA

### FREE PAPERS

12:50 Ocular redox status and visual function after treatment with an antioxidant mixture in patients with retinitis pigmentosa  
**Regina Rodrigo**, Spain

12:55 Complex functional and morphological evaluation of the retina after intravitreal administration of bone marrow-derived cells population in retinitis pigmentosa  
**Marta P. Wiącek**, Poland

13:00 Tau protein in the retina  
**Umur A. Kayabasi**, Turkey

13:05 Wide-based foveal pit- a normal variant or a predilection for maculopathy?  
**I Hsin Ma**, Taiwan

13:10 Efficacy of hyperbaric oxygen therapy on intraocular pressure and nerve fiber layer with type 2 diabetic patients: a prospective cohort study  
**Havva Kaldırım**, Turkey

13:15 Ultra wide-field retinal imaging in cytomegalovirus retinitis  
**John Paul Liscombe**, Spain

13:20 Q&A

13:30 - 14:30 **DIABETIC RETINOPATHY**  
Chairs: **Rufino Silva**, Portugal & **Francesco Boscia**, Italy

13:30 Comparison of FA and OCTA in DR  
**Javier Zarranz**, Spain

13:37 Ultra-widefield swept source OCTA in DR  
**Maria Cristina Parravano**, Italy

13:44 Diabetic retinopathy treated with anti-VEGF: results on clinical trials  
**Francesco Boscia**, Italy



## Saturday, November 9, 2019 (Continued)

13:30 - 14:30 **DIABETIC RETINOPATHY (Continued)**  
Chairs: **Rufino Silva**, Portugal & **Francesco Boscia**, Italy

- 13:51 Update on DRCR.net studies in DR  
**Itay Chowers**, Israel
- 13:58 Is it safe to space out injections when you are treating PDR with anti-VEGF alone?  
**Rufino Silva**, Portugal
- 14:05 Surgery in DME. when and how?  
**Jose García Arumí**, Spain
- 14:12 Discussion and clinical cases

14:30 - 15:30 **MYOPIA**  
Chairs: **Jose García Arumí**, Spain & **Jose Maria Ruiz-Moreno**, Spain

- 14:30 Myopic maculopathy; new classification Jose  
**Maria Ruiz-Moreno**, Spain
- 14:37 Factors influencing visual acuity in patients receiving anti VEGF for myopic CNV  
**Francesco Boscia**, Italy
- 14:44 Update on myopic CNV management  
**Choi-Mun Chan**, Singapore
- 14:51 The dome shaped macula and it's potential treatments  
**Itay Chowers**, Israel
- 14:58 When is surgery the option in myopic maculopathy?  
**Jose García Arumí**, Spain
- 15:05 Discussion

---

15:30 *Coffee Break*

---

15<sup>th</sup> **ISOPT** *Clinical*

The International Symposium on  
Ocular Pharmacology and Therapeutics



Valencia, Spain  
November 7-9, 2019

## Saturday, November 9, 2019 (Continued)

16:00 - 17:30

### CHALLENGING CASES

Chair: **Patricia Udaondo**, Spain

Middle age male with hypertension and visual disturbance

**Enrique García-Soler**, Spain

Unilateral vision loss

**Aida Navarro Navarro**, Spain

50 year old female with a retinal detachment

**Alexandru Placinta**, Spain

14 year old female with unilateral macular lesions and vision loss

**Miguel Ortiz**, Spain

81 year old female with bilateral floaters and blurred vision

**Ana Lopez-Montero**, Spain

Patient with low vision due to inherited retinal disease

**Alvaro Rallo**, Spain & **Sonia Peñarrocha**, Spain

---

17:00

*End of Day's Sessions*

---